Affimed N.V. · OTC:AFMDQ
Affimed — AACR 2022
21 slides from Affimed's conference presentation, Apr 10, 2022
Slide 1: Actualizing the Untapped Potential of the Innate Immune System
ACTUALIZING THE UNTAPPED POTENTIAL OF THE INNATE IMMUNE SYSTEM AACR 2022 Investor Update April 10, 2022
Slide 2: Forward-Looking Statements / Cautionary Note
Forward-Looking Statements / Cautionary Note This presentation and the accompanying oral commentary contain “forward-looking” statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation and the accompanying oral
Slide 3: Driving the revolution in cancer treatment
Driving the revolution in cancer treatment Inspired by the immense potential of the innate immune system, we are dedicated to unlocking profound possibilities through the development of our Innate Cell Engagers (ICE®)—bringing new hope to those whose lives have been forever changed by the impact of
Slide 4: Affimed: A Clinical-Stage Oncology Biotech Company Reimagining the Fight Against Cancer
Affimed: A Clinical-Stage Oncology Biotech Company that is Reimagining the Fight Against Cancer Challenges in immuno-oncology (I-O) Every disease state and tumor type is uniquely impacted by how well a patient’s immune system functions—I-O therapy that works for one patient may not work for others C
Slide 5: CD30+ Lymphomas: Treatment Challenges and Clinical Trial Update
CD30+ Lymphomas: Treatment Challenges and Clinical Trial Update Andreas Harstrick, CMO
Slide 6: Limited Treatment Options for Relapsed/Refractory Hodgkin Lymphoma
Historically, There Have Been Limited Treatment Options for Patients With Relapsed/Refractory Hodgkin Lymphoma Historical Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma 1st Salvage +/- Combination Autologous stem chemotherapy cell transplant 2nd Salvage + or or or Chemotherapy Radiotherap
Slide 7: Emerging Vacuum of Effective Options in the Relapsed Refractory Setting
Emerging Vacuum of Effective Options in the Relapsed Refractory Setting as BV and CPIs Move to Earlier Lines of Treatment Current Treatment Algorithm for Hodgkin Lymphoma1 First-Line Early ABVD OR First-Line Advanced AVD + brentuximab vedotin/2-4 cycles ABVD, restaging with PET-CT Transplant Eligibl
Slide 8: Unmet Need Among Heavily Pretreated RR HL Patients
There is an Unmet Need for Effective and Well-Tolerated Treatments Among Heavily Pretreated RR HL Patients • Treatment options become increasingly limited once patients have Treatment Options: failed chemotherapy, brentuximab vedotin, and checkpoint inhibitors1 – A significant need remains for patie
Slide 9: ICE AFM13 Combined with Cord Blood-Derived NK Cells
Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded Cord Blood-Derived Natural Killer Cells for Patients with Refractory/Relapsed CD30+ Lymphomas Based on data presented at AACR 2022: Y. Nieto et al., abstract/ presentation CT003 Additional details available at: www.clinicaltria
Slide 10: AFM13-complexed CB-Derived NK cells Treatment Schema
AFM13-complexed CB-Derived NK cells for Refractory/Relapsed CD30+ Lymphoma (NCT04074746) Treatment Schema Infusion of AFM13 3 dose levels CAR-like 1 x 106/kg CB-derived NK cells 1 x107/kg NK cells 1x108/kg • Fludarabine 30 • Preactivation (IL-12/IL-15/IL-18) mg/m2/day NK NK NK NK • Expand with uAPC
Slide 11: Patient Population
Patient Population Baseline Characteristics N=22 (Enrolled) Age, median (range) 40 (20–75) Gender (male/female) 15 / 7 Diagnosis (Hodgkin / T-NHL) 20 / 2 No. prior lines therapy, median (range) 7 (1–14) Prior brentuximab vedotin 22 Prior anti-PD-1 21 Prior SCT (autologous / allogeneic) 14 (9 / 5) Pr
Slide 12: Safety Profile
Safety Profile • No cases of cytokine release syndrome (CRS), neurotoxicity (ICANS) or graft-vs- host disease (GVHD) • No IRR of any grade in 40 infusions of AFM13-NK • 6 infusion-related reactions in 110 infusions of AFM13 alone (5.4%) • Myelotoxicity of lymphodepleting FluCy: • Neutropenia (63% G4
Slide 13: Antitumor Activity
Antitumor Activity % change of index lesion • 13/13 patients treated at the RP2D 100 responded (ORR 100%) 80 • 8 CR (62%), 5 PR (38%) 60 • 5 CR after C1 and 8 CR after C2 40 20 • 17/19 metabolic responses (ORR 89.5%) 0 • 10 CR, 7 PR -20 -40 -60 -80 -100 Responses evaluated by PET using Lyric criteri
Slide 14: Patient Case
Patient Case At Enrollment C1 D30 C2 D30 37 year/old male • Highly refractory Hodgkin • 10 prior lines of therapy, including: ABVD, GDP, ICE, HDC/ASCT, pembrolizumab, bendamustine-BV, BV/nivolumab, BV/everolimus and CAR-T • B symptoms at enrollment • Treated at dose level 3 Bulky diffuse PR CR lymph
Slide 15: Duration of Responses at RP2D
Duration of Responses at RP2D: Months after 1st AFM13- CB NK Infusion 8 9 7 14 15 16 Patient Number 17 Ongoing response 18 Subsequent SCT 19 Relapse/PD/death 13 Best Response: 12 CR 10 PR 11 0 2 4 6 8 10 12 Months Based on data presented at AACR 2022: Y. Nieto et al., abstract/ presentation CT003
Slide 16: AFM13-104 Initial Clinical Observations
AFM13-104 Initial Clinical Observations • Unprecedented response rate in patients with multi-refractory (chemotherapy, PD-1, Brentuximab) Hodgkin lymphoma • Sequential cycles of the treatment result in deepening of responses with a 62% CR rate at the RP2D after two cycles • Preliminary follow up ind
Slide 17: Closing Thoughts
Closing Thoughts Adi Hoess One (i
Slide 18: A Growing Pipeline Poised to Advance the Treatment of Cancer
A Growing Pipeline Poised to Advance the Treatment of Cancer Broad Pipeline of Wholly Owned and Partnered Programs Candidate Approach Indication Discovery Ph. 1 Ph. 2a Ph. 2b Status Monotherapy Peripheral T-cell lymphoma (AFM13-202) Registration Directed, Completed Enrollment AFM13 + Adoptive NK cel
Slide 19: Closing Thoughts and Next Steps
Closing Thoughts and Next Steps Unmet need and market opportunities Opportunity & next steps for AFM13-104 for CD30+ lymphomas CD30+ lymphomas comprise different subtypes: HL, PTCL, More patients and additional follow-up is coming on top of CTCL, DLBCL and FL already encouraging data Current t
Slide 20: Our Blueprint for Delivering Transformative, Indication-Specific Medicines
Our Blueprint for Delivering Transformative, Indication-Specific Medicines Pioneer Powerful ICE® Monotherapies In indications where the innate immune system is functional Combine ICE® With NK Cells Supplement patients with dysregulated innate immune systems with targeted cellular therapy Combine ICE
Slide 21: Thank you
Thank you 21